Details for Patent: 9,968,595
✉ Email this page to a colleague
Which drugs does patent 9,968,595 protect, and when does it expire?
Patent 9,968,595 protects TIBSOVO and is included in one NDA.
This patent has twenty-six patent family members in fifteen countries.
Summary for Patent: 9,968,595
Title: | Pharmaceutical compositions of therapeutically active compounds |
Abstract: | Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein. |
Inventor(s): | Gu; Chong-Hui (Waban, MA) |
Assignee: | AGIOS PHARMACEUTICALS, INC. (Cambridge, MA) |
Application Number: | 15/125,880 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,968,595 |
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Process; |
Drugs Protected by US Patent 9,968,595
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) | ⤷ Try a Trial | |||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) | ⤷ Try a Trial | |||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION | ⤷ Try a Trial | |||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | A METHOD FOR TREATING AML BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING IVOSIDENIB WHEREIN THE AML IS NEWLY DIAGNOSED AND CHARACTERIZED BY A MUTANT IDH1 AND THE COMPOSITION IS ADMINISTERED IN COMBINATION WITH AZACITIDINE | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,968,595
PCT Information | |||
PCT Filed | March 13, 2015 | PCT Application Number: | PCT/US2015/020349 |
PCT Publication Date: | September 17, 2015 | PCT Publication Number: | WO2015/138839 |
International Family Members for US Patent 9,968,595
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2015229214 | ⤷ Try a Trial | |||
Australia | 2019246824 | ⤷ Try a Trial | |||
Brazil | 112016021232 | ⤷ Try a Trial | |||
Canada | 2942072 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |